Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.

Cidara Therapeutics, Inc.

Cidara Therapeutics is a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing cancer and other serious diseases.

National Institutes of Health

CARB-X

Square 1 Bank

venBio Partners

Rock Springs Capital

Sabby Capital

5AM Ventures

Aisling Capital

RA Capital Management

Fidelity

Cidara Therapeutics

Today our treatment for adults with invasive candidiasis has been approved by the United Kingdom MHRA. Read here for more information on this milestone: https://brnw.ch/21wGuRc

In case you missed it, the European Commission approved our treatment for adults with invasive candidiasis, triggering an $11M milestone payment that we will use to continue the development of our Cloudbreak platform in oncology. Learn more about the approval: https://brnw.ch/21wFMcE

Today, we announced our treatment option for adults with invasive candidiasis has been approved in the European Union. Read more about this significant milestone for patients here: https://brnw.ch/21wFxOY

We’re excited to share we presented new preclinical data at the ESMO - European Society for Medical Oncology Immuno-Oncology Congress, demonstrating anti-tumor activity of our multi-specific CD73/PD-1 inhibitor drug-Fc conjugate (DFC) candidate. Read more: https://brnw.ch/21wF786 #ESMOImmuno23

COM:CIDARA